Pfizer launches pivotal study of alopecia areata candidate

|By:, SA News Editor

Pfizer (NYSE:PFE) initiates a Phase 2b/3 clinical trial evaluating Breakthrough Therapy-tagged PF-06651600, an oral JAK3 inhibitor, in patients with alopecia areata, an autoimmune disorder characterized by hair loss on the scalp, face or body.

The primary endpoint of the 660-subject, double-blind, placebo-controlled study is the proportion of patients achieving a score of 10 or less on a scale called Severity of Alopecia Tool (SALT) at week 24 compared to control. The estimated completion date is June 2021.

Related tickers: (NASDAQ:ACRS)(NASDAQ:CNCE)

Subscribe for full text news in your inbox